Φορτώνει......
RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1(185delAG) allele is a common inherited...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | J Clin Invest |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
American Society for Clinical Investigation
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4966309/ https://ncbi.nlm.nih.gov/pubmed/27454289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI87033 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|